In 2019, a new anti-VEGF agent, conbercept by Lumitin (China), was approved locally to treat wet AMD and reported to be safe and efficient (Cãlugãru and Cãlugãru, 2019; Liu et al., 2019). This evidence concerns the gene VEGFA and wet macular degeneration.